Literature DB >> 17085491

On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9.

Ornjira Aruksakunwong1, Maturos Malaisree, Panita Decha, Pornthep Sompornpisut, Vudhichai Parasuk, Somsak Pianwanit, Supot Hannongbua.   

Abstract

Aiming to understand, at the molecular level, why oseltamivir (OTV) cannot be used for inhibition of human influenza neuraminidase subtype N1 as effectively as for subtypes N2 and N9, molecular dynamics simulations were carried out for the three complexes, OTV-N1, OTV-N2, and OTV-N9. The three-dimensional OTV-N2 and OTV-N9 initial structures were represented by the x-ray structures, whereas that of OTV-N1, whose x-ray structure is not yet solved, was built up using the aligned sequence of H5N1 isolated from humans in Thailand with the x-ray structure of the N2-substrate as the template. In comparison to the OTV-N2 and OTV-N9 complexes, dramatic changes were observed in the OTV conformation in the OTV-N1 complex in which two of its bulky side chains, N-acethyl (-NHAc) and 1-ethylproxy group (-OCHEt2), were rotated to adjust the size to fit into the N1 catalytic site. This change leads directly to the rearrangements of the OTV's environment, which are i), distances to its neighbors, W-178 and E-227, are shorter whereas those to residues R-224, E-276, and E-292 are longer; ii), hydrogen bonds to the two nearest neighbors, R-224 and E-276, are still conserved in distance and number as well as percentage occupation; iii), the calculated ligand/enzyme binding free energies of -7.20, -13.44, and -13.29 kcal/mol agree with their inhibitory activities in terms of the experimental IC50 of 36.1-53.2 nM, 1.9-2.7 nM, and 9.5-17.7 nM for the OTV-N1, OTV-N2, and OTV-N9 complexes, respectively; and iv), hydrogen-bond breaking and creation between the OTV and neighborhood residues are accordingly in agreement with the ligand solvation/desolvation taking place in the catalytic site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085491      PMCID: PMC1779986          DOI: 10.1529/biophysj.106.092528

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  18 in total

1.  Analysis of inhibitor binding in influenza virus neuraminidase.

Authors:  B J Smith; P M Colman; M Von Itzstein; B Danylec; J N Varghese
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 2.  Resistance of influenza viruses to neuraminidase inhibitors--a review.

Authors:  J L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2000-07       Impact factor: 5.970

3.  Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.

Authors:  M J Todd; I Luque; A Velázquez-Campoy; E Freire
Journal:  Biochemistry       Date:  2000-10-03       Impact factor: 3.162

4.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.

Authors:  J N Varghese; J L McKimm-Breschkin; J B Caldwell; A A Kortt; P M Colman
Journal:  Proteins       Date:  1992-11

5.  Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand.

Authors:  Pilaipan Puthavathana; Prasert Auewarakul; Pakapak Chor Charoenying; Kantima Sangsiriwut; Phisanu Pooruk; Kobporn Boonnak; Raweewan Khanyok; Pranee Thawachsupa; Rungrueng Kijphati; Pathom Sawanpanyalert
Journal:  J Gen Virol       Date:  2005-02       Impact factor: 3.891

6.  Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.

Authors:  E A Govorkova; I A Leneva; O G Goloubeva; K Bush; R G Webster
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.

Authors:  P M Colman; P A Hoyne; M C Lawrence
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

9.  H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes.

Authors:  Ya Ha; David J Stevens; John J Skehel; Don C Wiley
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

Review 10.  Influenza virus neuraminidase inhibitors.

Authors:  L V Gubareva; L Kaiser; F G Hayden
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

View more
  10 in total

1.  Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study.

Authors:  Zhiwei Yang; Gang Yang; Lijun Zhou
Journal:  J Comput Aided Mol Des       Date:  2013-11-12       Impact factor: 3.686

2.  Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.

Authors:  Ryo Takano; Maki Kiso; Manabu Igarashi; Quynh Mai Le; Masakazu Sekijima; Kimihito Ito; Ayato Takada; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2012-10-10       Impact factor: 5.226

3.  In-silico design and molecular docking evaluation of peptides derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of Hepatitis E virus capsid protein.

Authors:  Carolina Quintero-Gil; Jaime Parra-Suescún; Albeiro Lopez-Herrera; Sergio Orduz
Journal:  Virusdisease       Date:  2017-06-09

4.  Molecular-level simulation of pandemic influenza glycoproteins.

Authors:  Rommie E Amaro; Wilfred W Li
Journal:  Methods Mol Biol       Date:  2012

5.  Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.

Authors:  Ly Le; Eric Lee; Klaus Schulten; Thanh N Truong
Journal:  PLoS Curr       Date:  2009-08-27

6.  Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Authors:  Mark Holodniy; Scott R Penzak; Timothy M Straight; Richard T Davey; Kelvin K Lee; Matthew Bidwell Goetz; Dennis W Raisch; Francesca Cunningham; Emil T Lin; Noemi Olivo; Lawrence R Deyton
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

7.  Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors.

Authors:  Zhiwei Yang; Gang Yang; Yuangang Zu; Yujie Fu; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2010-12-01       Impact factor: 5.923

8.  Effects of water models on binding affinity: evidence from all-atom simulation of binding of tamiflu to A/H5N1 neuraminidase.

Authors:  Trang Truc Nguyen; Man Hoang Viet; Mai Suan Li
Journal:  ScientificWorldJournal       Date:  2014-02-02

9.  Inhibitory effect and possible mechanism of action of patchouli alcohol against influenza A (H2N2) virus.

Authors:  Huaxing Wu; Beili Li; Xue Wang; Mingyuan Jin; Guonian Wang
Journal:  Molecules       Date:  2011-08-03       Impact factor: 4.411

10.  Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.

Authors:  Morgan Lawrenz; Jeff Wereszczynski; Rommie Amaro; Ross Walker; Adrian Roitberg; J Andrew McCammon
Journal:  Proteins       Date:  2010-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.